select trial semaglutide cardiovascular outcomes non-diabetic 2023 Long-term kidney of in obesity and disease in the SOUL (Semaglutide cardiOvascular oUtcomes triaL)

This article examines the evidence for visceral fat reduction with GLP-1 therapy, the mechanisms involved, and clinical implications for patients with central obesity and cardiometabolic disease

While further study is needed to explicitly link semaglutide to lipedema treatment outcomes, its ability to reduce general body weight and improve insulin sensitivity makes it an appealing alternative for symptom management

The implications for cardiorespiratory fitness, a key predictor of overall health and mortality risk, remain unclear

Inadequate hydration can also slow digestion and increase fatigue, both of which intensify hunger signals